187973-60-0

Usage

Uses

Used in Pharmaceutical Research:
6-iodopyridazin-3-amine is utilized as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic effects. Its structural attributes, including the presence of an iodine atom and an amine group, facilitate its integration into diverse medicinal compounds.
Used in Organic Synthesis:
In the field of organic synthesis, 6-iodopyridazin-3-amine is employed as a building block for constructing more complex organic molecules. Its reactivity and structural components make it a valuable component in the synthesis of a wide array of chemical entities, including those with potential applications in materials science, agrochemicals, and specialty chemicals.
Used in Medicinal Chemistry:
6-iodopyridazin-3-amine is leveraged in medicinal chemistry as a precursor to design and develop novel bioactive molecules. Its unique structural elements can be manipulated to create compounds with specific binding affinities and selectivity towards biological targets, which is crucial for the discovery of new therapeutic agents.
Used in Radiopharmaceuticals:
Given the presence of an iodine atom, 6-iodopyridazin-3-amine can be used in the development of radiopharmaceuticals, particularly those labeled with radioactive isotopes of iodine. This application is significant in the field of nuclear medicine for diagnostic and therapeutic purposes, such as in positron emission tomography (PET) imaging.
Used in Chemical Reagents:
6-iodopyridazin-3-amine may also serve as a specialty chemical reagent in various chemical processes, including as a catalyst or a reactant in specific organic reactions, due to its unique combination of functional groups.

Upstream product

• 5469-69-2 6-chloro-pyridazin-3-ylamine 

Downstream Products

• 188692-52-6 2-(4-Cyclohexyl-phenyl)-6-iodo-imidazo[1,2-b]pyridazine 
• 188692-49-1 2-(4-tert-Butyl-phenyl)-6-iodo-imidazo[1,2-b]pyridazine 
• 188692-55-9 2-([1,1'-biphenyl]-4-yl)-6-iodoimidazo[1,2-b]pyridazine 
• 188692-46-8 6-Iodo-2-phenyl-imidazo[1,2-b]pyridazine 
• 188692-58-2 6-Iodo-2-(4-iodo-phenyl)-imidazo[1,2-b]pyridazine 
• 105538-02-1 3-amino-6-(thiophen-3-yl)pyridazine 
• 105538-07-6 3-amino-6-(4-fluorophenyl)pyridazine 
• 58059-47-5 3-amino-6-(p-chlorophenyl)pyridazine 
• 4776-87-8 3-amino-6-(4'-methoxyphenyl)pyridazine 
• 102627-28-1 6-(3-(trifluoromethyl)phenyl)pyridazin-3-amine 
• 14966-91-7 3-amino-6-phenylpyridazine 
• 1005786-10-6 ethyl 6-iodoimidazo[1,2-b]pyridazine-2-carboxylate 
• 1005788-25-9 (6-iodoimidazo[1,2-b]pyridazin-2-yl)methanol 
• 1005785-69-2 ethyl (6-iodoimidazo[1,2-b]pyridazin-2-yl)carbamate 

Relevant academic research and scientific papers

Macrocyclic glutaminase GLS1 inhibitor or pharmaceutically acceptable salt thereof and preparation method and application thereof

The invention relates to the field of biological medicine, in particular to a series of macrocyclic glutaminase inhibitors, a synthesis method and medical application thereof, and particularly relatesto prevention or treatment of glutaminase related diseases. Meanwhile, the inventor performs a series of in-vitro anti-tumor activity evaluation on the synthesized compounds, and particularly, most of the compounds have good inhibitory activity on cancer cells.

BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER

A compound of Formula (I) or a pharmaceutically acceptable salt thereof, where R1 can be hydro, methoxy, difluoromethoxy or trifluoromethoxy; R2 can be hydro, methoxy, trifluoromethoxy or trifluoromethyl; and R3 can be hyd

PYRROLIDINO HETEROCYCLES

The invention relates to compounds of formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.

Development of new highly potent imidazo[1,2-b[pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1

Using a structure-based design approach, we have developed a new series of imidazo[1,2-b]pyridazines, targeting the calcium-dependent protein kinase-1 (CDPK1) from Toxoplasma gondii. Twenty derivatives were thus synthesized. Structure-activity relationships and docking studies confirmed the binding mode of these inhibitors within the ATP binding pocket of TgCDPK1. Two lead compounds (16a and 16f) were then identified, which were able to block TgCDPK1 enzymatic activity at low nanomolar concentrations, with a good selectivity profile against a panel of mammalian kinases. The potential of these inhibitors was confirmed in vitro on T. gondii growth, with EC50 values of 100 nM and 70 nM, respectively. These best candidates also displayed low toxicity to mammalian cells and were selected for further in vivo investigations on murine model of acute toxoplasmosis.

IMIDAZOLE DERIVATIVES

The present invention relates to compounds of formula (I), wherein A, B, R1 and R2 are as defined herein before.

PYRROLIDINO HETEROCYCLES

The invention relates to compounds of formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.

Synthesis and in vitro evaluation of imidazo[1,2- b ]pyridazines as ligands for β-amyloid plaques

A series of imidazo[1,2-b]pyridazine derivatives were synthesized and evaluated for binding to amyloid plaques in vitro using synthetic aggregates of Aβ1?40. Binding affinities of these compounds were found to range from 11.0 to >1000 nM, depending on the various substitution patterns in the 6-position and 2-position. 2-(4′-Dimethylaminophenyl)-6- (methylthio)imidazo[1,2-b]pyridazine (4) showed high binding affinity (K i = 11.0 nM) and might be useful for the development of novel positron emission tomography radiotracers for imaging Aβ plaques.

cMET INHIBITORS

Compounds of the following formula are provided for use with cMET: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES

The present invention provides a process for preparing benzimidazole thiophene compounds of formula I. Intermediates used in the process are also claimed.

A new approach towards the synthesis of 3-amino-6- (hetero)arylpyridazines based on palladium catalyzed cross-coupling reactions

The synthesis of 3-amino-6-(hetero)arylpyridazines via palladium catalyzed cross-coupling reactions (Suzuki, Stille) on 3-amino-6- chloropyridazine (1a) and 3-amino-6-iodopyridazine (1b) has been investigated. Comparison of the results shows that there is